Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H1 2020, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.
Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 14, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Kidney Fibrosis - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular...
Catenin Beta 1 - Pipeline Review, H1 2020 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 – Pipeline...
Hernia Repair Devices - Medical Devices Pipeline Assessment, 2020 Summary Hernia Repair Devices are surgical implants used to give extra support to the hernia affected tissues. Medical Devices sector report, “Hernia Repair Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive...
Gastric Ulcers - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2020, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.